Developing cortisol modulators for a broad range of serious diseases, including endocrine, metabolic, oncologic, and psychiatric disorders
We lead the field in the research and development of selective glucocorticoid receptor (GR) antagonists.
We are committed to developing novel medications for patients suffering from diseases driven by cortisol dysregulation.
Learn MoreWe foster a diverse and collaborative environment focused on developing novel therapies that help treat people with serious unmet medical needs.
Learn More